Latest News & Events
Hemanext successfully closes series a equity funding round, bringing total raised to more than $100 million
Leading Blood Storage Innovator Expanded Series A Round to Accommodate Interest from Noted Private...
Hemanext Announces that Hypoxic Blood Storage Study has been Recognized as Best Original Research Paper by AABB
Research supports Hemanext’s aim to improve clinical outcomes of transfusion recipients with its...
Hemanext® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System
Company to launch Hemanext ONE® RBC Processing and Storage System in select European markets in...
Senior Director of Transfusion Medicine at Johns Hopkins University Brings Global Experience in...
Current and prospective investors access to the investor Portal
COVID 19 Updates
Follow the course of COVID-19 and locate where to donate blood
View educational material and interesting presentations
Numerous studies pertaining to clinical implications of storage lesion suggest a linkage to hyper-coagulability, inflammation, impaired perfusion, immuno-modulation, organ dysfunction13, and mortality14.